Year: 2021
Type: article
Abstract: Non-metastatic prostate cancer presents unique challenges in medical decision making because of the generally favourable oncological prognosis—more than 98% 10-year cancer-specific survival—counterbalanced by the morbidity of treatment,1 including urinary incontinence and sexual dysfunction. As a result, the accepted standard of care ranges from active surveillance (ie, careful monitoring) to multimodal therapy that can include a combination of surgery, radiation, and hormonal therapy. Patients with non-metastatic prostate cancer face the difficult task of weighing short-term and possibly long-term side-effects against the risk of metastases and death within 10–20 years.
Source: The Lancet Digital Health
Authors: Grant M Henning, Eric H Kim
Institution: Washington University in St. Louis
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,000
OpenAlex ID: W3126828595